Prosecution Insights
Last updated: October 02, 2026

Examiner: WEDDINGTON, KEVIN E

Tech Center 1600 • Art Units: 1613 1614 1621 1629 1644

This examiner grants 75% of resolved cases

Analysis

Kevin E. Weddington is an examiner in Tech Center 1600, specifically Art Unit 1613. His professional record includes 1473 resolved cases, which is an exceptionally large data set. The allowance rate for Weddington is 75.2 percent, indicating that a high percentage of applications result in a patent grant. This rate provides a strong expectation of success for practitioners in this unit.

The interview lift for Weddington is 9.8 percent. This positive lift indicates that direct communication is a beneficial strategy, even with an already high allowance rate of 75.2 percent. While the lift is more modest than some other examiners, it still suggests that interviews are a productive way to resolve remaining issues in the 1473 resolved cases. Practitioners should consider this a useful tactical option in Art Unit 1613.

The median days to allowance is 903. This timeline is relatively efficient for reaching a final resolution. The combination of a 903-day median and a 75.2 percent allowance rate makes Art Unit 1613 a favorable environment for patent prosecution. The large volume of cases ensures that these metrics are a reliable reflection of Weddington's long-term examination tendencies within Tech Center 1600.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

75.2%
Allow Rate
+15.2% vs TC avg
1,493
Total Applications
+9.8%
Interview Lift
903
Avg Prosecution Days
Based on 1473 resolved cases, 2023–2026

Rejection Statute Breakdown

1.4%
§101 Eligibility
17.0%
§102 Novelty
28.3%
§103 Obviousness
28.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19684927 BUPROPION AS A MODULATOR OF DRUG ACTIVITY Non-Final OA ANTECIP BIOVENTURES II LLC
18591870 POLYAMINO IODINATED COMPOUNDS AND RADIOPAQUE HYDROGELS FORMED THEREFROM Non-Final OA Boston Scientific Scimed, Inc.
18043436 N-Linked Glycosylation Inhibitors and Methods of Using Same Non-Final OA YALE UNIVERSITY
18217821 LIPID EMULSIONS FOR PARENTERAL NUTRITION Non-Final OA BAXTER HEALTHCARE SA
18251827 PHARMACEUTICAL COMPOSITION FOR TREATING LEUKEMIA COMPRISING FLT3 INHIBITOR Final Rejection HANMI PHARM. CO., LTD.
18818701 TRICYCLIC COMPOUNDS Non-Final OA Jacobio Pharmaceuticals Co., Ltd.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month